Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Autoantibody Status Guides Treatment in Myasthenia Gravis

By LabMedica International staff writers
Posted on 20 Dec 2023

Autoantibody status plays a significant role in diagnosis and therapy decisions for myasthenia gravis (MG), an immune-mediated neuromuscular junction disorder. The key serological markers in MG are antibodies against nicotinic acetylcholine receptors (AChR), which are found in about 85% of cases, and antibodies against muscle-specific kinase (MuSK), which are observed in approximately 6% of cases, the majority of which are anti-AChR negative. 15% of MG cases are seronegative. The antibody-mediated processes in MG result in the loss of functional AChR at the motor endplate, either through direct blocking, antigen modulation, or complement-mediated damage of the muscle membranes. Anti-AChR antibodies belong to the IgG1 subclass and can activate the complement cascade. In AChR antibody-positive cases, complement-inhibiting drugs are among the recommended therapies. On the other hand, anti-MuSK antibodies belong to the non-complement binding IgG4 subclass, as a result of which complement inhibitors are ineffective for this form. Hence, therapy selection should consider the autoantibody status along with disease activity, thymus pathology, and the patient’s age.

Currently, the gold standard for detection of anti-AChR and MuSK antibodies is radioimmunoprecipitation assay (RIPA) although it comes with a disadvantage of the need for radioactive reagents. Cell-based indirect immunofluorescence assays (CBAs) offer a viable alternative that is easier to implement. EUROIMMUN (Lübeck, Germany) has developed CBAs based on transfected human cell lines expressing the corresponding target antigens AChR (adult: AChR-E and fetal: AChR-G) and MuSK. In an evaluation study published in the Journal of the Neurological Sciences, the EUROIMMUN Anti-AChR CBA demonstrated similarly excellent specificity and a significantly higher sensitivity for MG compared to RIPA, detecting anti-AChR in 21% of patients otherwise considered to be seronegative.

In a further analysis, the Anti-AChR and Anti-MuSK CBAs demonstrated high positive and 100% negative agreement with RIPA in patients with clinically confirmed MG. CBAs thus provide equivalent or superior performance to RIPA without the use of radioactive materials. Moreover, anti-AChR and anti-MuSK antibodies can be analyzed simultaneously using the EUROIMMUN Myasthenia gravis Mosaic 2, which provides a composite of CBAs for adult/fetal AChR and MuSK together with a control substrate. This test is currently the only commercially available multiparameter assay for anti-AChR and anti-MuSK. The CBAs are CE-marked. The CBA procedure is simple and can be performed in any laboratory familiar with indirect immunofluorescence. There are automation options available to aid the processing and evaluation, allowing for the assay’s smooth integration into laboratory routines.

Related Links:
EUROIMMUN

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.